Efficacy of an Oral Contraceptive Containing EE 0.03 mg and CMA 2 mg (Belara) in Moderate Acne Resolution: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial

    May 2009 in “ Contraception ”
    Gerd Plewig, W. J. Cunliffe, Natascha Binder, Kornelia Höschen
    Studysummary This study found that the combined oral contraceptive containing ethinyl estradiol and chlormadinone acetate was effective in reducing moderate papulopustular acne and other androgen-related skin disorders compared to placebo. Our plain-language summary of this paper — not a Tressless recommendation.
    The study evaluated the effectiveness of an oral contraceptive containing ethinyl estradiol (EE) 0.03 mg and chlormadinone acetate (CMA) 2 mg (Belara®) in treating moderate acne. In a randomized, double-blind, placebo-controlled Phase III trial involving 377 women, 64.1% of those treated with EE/CMA showed a reduction of at least 50% in facial papules/pustules compared to 43.7% in the placebo group. The EE/CMA group also experienced significant reductions in comedonal lesions, acne on the décolleté and back, and other androgen-related skin disorders. The study concluded that EE/CMA is an effective treatment for moderate papulopustular acne and related conditions.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results